CD274 and non-small cell lung carcinoma: Using a combination of atezolizumab and chemotherapy as first-line treatment has improved the progression-free survival of patients with NSCLC, regardless of the programmed death-ligand 1 (PD-L1) expression level.[1] A combination of chemoradiotherapy and durvalumab, an anti-PD-L1 inhibitor, is highly efficacious,[2] suggesting that both radiation and chemotherapy have a synergistic effect with PD-L1 inhibitors in NSCLC.